Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

PROSTATE CANCER IN 2019

Progress in therapy across the spectrum of advanced prostate cancer

Nature Reviews Urology volume 17, pages 71–72 (2020)Cite this article

Subjects

In men with hormone-sensitive prostate cancer, enzalutamide and apalutamide improve overall survival compared with androgen deprivation therapy alone. Also, radiotherapy of the primary tumour is beneficial in patients with low tumour burden. In the non-metastatic castration-resistant setting, a positive trial for darolutamide was reported. In the metastatic castration-resistant setting, the role of cabazitaxel in treatment sequencing was clarified.

Key advances

  • The phase III trials ENZAMET, ARCHES and TITAN demonstrated a significant benefit for the addition of enzalutamide or apalutamide to androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer2,3,4.

  • The STAMPEDE trial showed practice-changing results for the addition of prostate radiotherapy to standard-of-care systemic therapy in metastatic hormone-sensitive prostate cancer5.

  • The ARAMIS trial demonstrated a significant benefit for the novel androgen receptor (AR) antagonist darolutamide in non-metastatic castration-resistant prostate cancer8.

  • The CARD trial set a new standard of care for cabazitaxel as the third-line treatment for metastatic castration-resistant prostate cancer in patients who had progressed on docetaxel and AR-targeted therapy10.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Prostate cancer treatment landscape including advances in the past year.

References

  1. McNamara, M. et al. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis. 21, 306–318 (2018).

    Article  CAS  Google Scholar 

  2. Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).

    Article  Google Scholar 

  3. Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974–2986 (2019).

    Article  Google Scholar 

  4. Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).

    Article  CAS  Google Scholar 

  5. Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353–2366 (2018).

    Article  Google Scholar 

  6. Boeve, L. M. S. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur. Urol. 75, 410–418 (2019).

    Article  Google Scholar 

  7. Higano, C. Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients? Nat. Rev. Urol. 16, 335–336 (2019).

    Article  Google Scholar 

  8. Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. 380, 1235–1246 (2019).

    Article  CAS  Google Scholar 

  9. Attard, G. et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol. 36, 2639–2646 (2018).

    Article  CAS  Google Scholar 

  10. de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911206 (2019).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank A. Karon for editorial assistance.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

    Sabine Schmid & Aurelius Omlin

  2. Princess Margret Cancer Centre, Toronto, Ontario, Canada

    Sabine Schmid

  3. Medical Faculty, University of Bern, Bern, Switzerland

    Aurelius Omlin

Authors
  1. Sabine Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurelius Omlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurelius Omlin.

Ethics declarations

Competing interests

A.O. has advisory roles (compensated, institutional) with Astellas, AstraZeneca, Bayer, Janssen, Merck, Sharp and Dohme (MSD), Pfizer, Roche and Sanofi Aventis, receives research support (institutional) from Janssen and Teva, receives travel support for medical conferences from Astellas, Bayer, Janssen and Sanofi Aventis, and serves as a speaker (compensated, institutional) for Bayer and Astellas. S.S. has advisory roles (compensated, institutional) with Boehringer Ingelheim and MSD, receives research support (institutional) from AstraZeneca and Bristol-Myers Squibb (BMS), and receives travel support for medical conferences from Boehringer Ingelheim, MSD and Takeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmid, S., Omlin, A. Progress in therapy across the spectrum of advanced prostate cancer. Nat Rev Urol 17, 71–72 (2020). https://doi.org/10.1038/s41585-019-0270-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0270-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer